Salience, Sensemaking, and Setting in Psilocybin Microdosing: Methodological Lessons and Preliminary Findings of a Mixed Method Qualitative Study

Research on classical psychedelics restarted in earnest from the 1990s after a long hiatus, driven by findings in psychedelic-assisted psychotherapy and by anecdotal and survey reports suggesting benefits for cognition, creativity, mindfulness and several psychiatric conditions. One commonly reported pattern of use is microdosing, defined as repeated use of sub-threshold doses intended to avoid overt psychedelic effects, but there is no consensus on what constitutes a microdose and observational reports are heterogeneous. The field faces substantial methodological challenges, including legal constraints, expectancy effects and difficulties with blinding, and recent critiques have emphasised non-representative sampling and unclear boundaries between therapeutic process and adverse events. Oblak and colleagues present a pilot, proof-of-principle qualitative study that aims to characterise the lived experience of people who self-administer psilocybin microdoses in naturalistic settings. The study combines momentary ecological assessment (repeated in-the-moment sampling) with detailed phenomenological interviews to examine both moment-to-moment experience and retrospective sensemaking, and to derive methodological lessons for larger mixed-methods investigations and harm-mitigation strategies.

The investigators recruited 13 participants (nine women) via a drug-harm-reduction non-governmental organisation; all had chosen to microdose psilocybin independently and consented to monitoring. The sample included people microdosing for depression, cognitive enhancement, somatic symptom relief and self-knowledge. Three participants did not complete the entire protocol: one discontinued after acute suicidal ideation and was referred to clinical care, one was excluded for poor adherence, and one withdrew because repeated prompts exacerbated a Crohn's flare. Data collection combined ecological momentary assessment delivered through the M-Path app and serial phenomenological interviews. Baseline lifeworld interviews grounded participants' pre-microdosing experiential profiles. Baseline momentary sampling comprised four days spread over two weeks, with five prompts per sampling day. When participants began microdosing, the researchers collected momentary reports on on-days and off-days (intervals varied by individual regimen), followed by interviews after two and four on-days and a debriefing interview. Dosages and regimens varied by participant and no biological assays (blood levels) were performed. Analysis used grounded theory: the team conducted 49 interviews, coded transcripts and sampling data, grouped codes into themes, and built a network model to describe relationships among themes. Themes were organised into phenomenology, sensemaking, biological factors and social factors. The investigators drew on lifeworld analysis and psychopathological phenomenology to structure the interviews and to capture participants' embodied, temporal and social experiences.

The participants' reports were heterogeneous and often context-dependent. Across the sample, investigators identified recurrent experiential changes: a loosening of mental structures (thoughts felt less forceful, with tangential streams of consciousness), heightened salience of external stimuli (mundane events becoming strikingly interesting, but sometimes producing sensory overload), increased flexible cognition (creativity, novel associations) and decreased stable cognition (reduced sustained attention and poorer inhibitory control). Social cognition was also altered, with increased awareness of implicit social dynamics and occasional adoption of new or ego-dystonic affective states and roles. Momentary ecological assessment and retrospective interviews produced contrasting appraisals. Sampling data tended to record negative or distressing moments — poor focus, overwhelm, anxiety and sensory amplification — whereas debriefing interviews were generally more positive, emphasising gentle insights, increased self-observation and appreciation for new possibilities. Several concrete examples illustrate this contrast: a participant who described scattered, impaired focus during in-the-moment sampling later characterised the overall period as "completely average"; another reported persistent low mood in samples but retrospectively framed the microdosing period as ultimately valuable because it produced felt experience. Notably, multiple participants exceeded what investigators would classify as strict microdoses, reporting 'threshold' or 'meso-dosing' experiences (examples included ingestion of ≈200–300 mg dried mushroom), which were accompanied by pronounced perceptual alterations and psychosis-like phenomena in some cases. Case reports include transient hyperreflexivity, time-slowing, visual motion of objects and emergent odd or over-interpreted meanings in conversation. One participant experienced three days of intense physiological anxiety at the end of the microdosing period; another developed suicidal ideation and discontinued microdosing and study participation. No systematic physical effects were reported aside from that anxiety episode. Qualitatively, participants emphasised the role of context: well-structured, predictable environments (for example, a quiet library) tended to support productive engagement and positive appraisals of altered cognition, whereas loosely structured, unpredictable settings often precipitated overwhelm and negative experiences. Expectancies and prior attitudes also shaped narratives: participants generally held positive beliefs about psychedelics and often framed microdosing effects through familiar practices such as mindfulness meditation.

The investigators interpret their findings as highlighting both substantive phenomenological features of self-directed psilocybin microdosing and methodological implications for research. They argue that microdosing-related changes map onto a shift from stable to flexible cognition, plausibly mediated by alterations in salience — that is, what captures attention and is processed deeply. Increased salience may foster creativity and momentary engagement with mundane tasks, but it can also produce distractibility, sensory overload and experiences that resemble psychotic phenomena when dosing approaches threshold levels. A central methodological observation is the systematic divergence between momentary (sampling) and retrospective reports. The researchers situate this in phenomenological and memory literature: remembered accounts are reconstructive and shaped by sensemaking and cultural narratives (a 'folk psychiatry' of psychedelics), whereas momentary sampling captures the experiencing self and may reveal negative or destabilising moments that retrospective accounts downplay. Consequently, the authors recommend triangulating methods — collecting baseline lifeworld data, combining ecological sampling with interviews, and studying local narratives about psychedelics — to reduce bias and better characterise harms and benefits. The paper acknowledges key limitations: the small, self-selected sample prevents causal inference, dosing and regimens varied and were not biologically verified, and participants' favourable expectancies likely influenced retrospective appraisals. The investigators caution that threshold dosing occurred in this cohort, complicating attributions to microdosing per se. They suggest that attention to set and setting may help mitigate risks and shape outcomes, and that larger-scale mixed-methods studies are needed to clarify how context, expectancy and dosing interact to produce both beneficial and adverse lived experiences.

Oblak and colleagues present a qualitative, mixed-methods pilot that documents varied and context-sensitive lived experiences among people who self-administer psilocybin microdoses. Key phenomenological findings include loosening of mental structures, increased environmental salience, greater flexible cognition alongside reduced stable cognition, and occasional ego-dystonic or psychosis-like phenomena when dosing approached threshold. Methodologically, the study demonstrates that momentary ecological assessment can reveal negative experiences that retrospective interviews tend to reframe or soften, and it recommends collecting baseline lifeworld data, mapping folk narratives about psychedelics, and combining in-the-moment and retrospective methods in future research. The authors conclude that larger, systematic mixed-methods studies are required to characterise benefits, risks and contextual moderators of psilocybin microdosing and to inform harm-mitigation strategies.